Ocph.Ca
OCPH.CA is a pharmaceutical company that generates revenue primarily through the development and commercialization of prescription drugs and related healthcare products.
Business. OCPH.CA is a pharmaceutical company that generates revenue primarily through the development and commercialization of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OCPH.CA is a pharmaceutical company that generates revenue primarily through the development and commercialization of prescription drugs and related healthcare products.
OCPH.CA maintains a relatively strong liquidity position, with a current ratio of 2.06, indicating that it has sufficient current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its short-term liquidity.
The company's profitability is robust, with a return on equity (ROE) of 29.86% and a return on assets (ROA) of 15.91%. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that OCPH.CA is effectively utilizing its equity and assets to generate returns.
OCPH.CA's financial data does not provide a breakdown of revenue by business segment or geographic region, so it is not possible to assess the company's exposure to specific markets or product lines. However, the absence of such data suggests that the company may have a relatively concentrated revenue base, which could pose a risk if demand for its core products declines.
The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The capital expenditure of -16.46 million EGP suggests that the company is not currently investing heavily in new projects or infrastructure, which may indicate a focus on cost control or a lack of expansion opportunities.
OCPH.CA's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.41 is relatively low, indicating a conservative capital structure. However, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near term, which could lead to dilution for existing shareholders.
There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of such information suggests that OCPH.CA is currently operating in a stable environment without major disruptions.
- OCPH.CA has a strong return on equity and return on assets, indicating effective use of capital.
- The company's liquidity position is medium, with a current ratio of 2.06, but a negative net cash position after debt.
- There is no segment or geographic revenue breakdown available, suggesting potential concentration risk.
- The company's capital expenditure is negative, indicating a lack of investment in new projects.
- The risk of dilution is low, but the company may need to raise additional capital in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- OCPH.CA Market data — financials · 2026-05-28